Scientific Technology and R&D

Technology Platform

Integrated proprietary R&D engine anchored around our deep understanding of tumor immunology, continuously driving the discovery and development of immunotherapies.

  • We have established an integrated in-house R&D platform that covers target selection and validation, drug discovery, high-throughput screening, molecule design, preclinical studies, CMC and IND-enabling capabilities. Our platform enables us to continuously discover and develop next-generation innovative oncology therapies and move them forward to the clinical stage. The R&D engine includes a proprietary mAb-Trap bispecific platform, advanced hybridoma technology, high-throughput screening, strong immunoassay and bioassay technology, efficient cell line development and antibody production, as well as robust CMC and manufacturing capacity, which allow us to efficiently conduct screening for leading compounds and druggability analysis, cost-effectively manufacture high-quality drug candidates in-house, and provide firm support for our drug development efforts.

  • 我们坚实的药物发现及临床前平台包括先进的杂交瘤技术、高通量筛选、强大的免疫测定和生物检测技术,以及自有的双特异性单克隆抗体-受体重组蛋白平台。该一体化平台使我们能够有效地进行药物筛选和成药性分析。我们建立的临床前开发功能使我们能够在动物中进行关于体内药效、临床前药代动力学和药效学以及毒理学的概念验证研究。凭藉我们强大的药物发现和临床前开发能力,我们正在开发十多款处于不同阶段的候选药物。该等内部开发的候选药物一旦成功推向市场,均有潜力成为全球首创或同类最佳药物。

Product Pipeline
Program
Target (Modality)
Indication(s)
DiscoveryPreclinicalIND/IND-
Enabling
Phase
Ia/Ⅰ
Phase
Ib/Ⅱ
Phase Ⅲ/
Pivotal
Commercial Rights
IMM01 + Azacitidine
CD47
(SIRPα-Fc fusion protein)
AML, MDS, CMML
China (NMPA)
Global
IMM01 + Azacitidine
View Details
IMM01 + Tislelizumab
CD47+PD-1
cHL, Solid tumor
China (NMPA)
Global
IMM01 + Tislelizumab
View Details
IMM01 + Inetetamab
CD47+HER2
HER2-positive solid tumors
China (NMPA)
Global
IMM01 + Bortezomib+ Dexamethasonum
CD47
MM
China (NMPA)
Global
IMM0306 Monotherapy
CD47xCD20 (Bispecific molecule)
Indolent B-NHL
China (NMPA) / US (FDA)
Global
IMM0306 Monotherapy
View Details
IMM0306 + Lenalidomide
CD47xCD20 (Bispecific molecule)
B-NHL
China (NMPA)
Global
IMM0306 + Lenalidomide
View Details
IMM2902
CD47xHER2 (Bispecific molecule)
HER2-positive and low-expressing solid tumors
China (NMPA) / US (FDA)
Global
IMM2902
View Details
IMM2520
CD47xPD-L1 (Bispecific molecule)
Solid tumors
China (NMPA) / US (FDA)
Global
IMM2520
View Details
IMM47
CD24 (mAb)
Solid tumors
China (NMPA) / US (FDA)
Global
IMM47
View Details
IMM4701
CD47xCD24 (Bispecific molecule)
Solid tumors
Global
IMM4701
View Details
IMM2547
CD24xPD-L1 (Bispecific molecule)
Solid tumors
Global
IMM51
IL-8 (mAb)
Solid tumors
Global
IMM38
NKG2A
(mAb)
Solid tumors
Global
IMM50
PSGL-1
(mAb)
Solid tumors
Global
IMM62
Undisclosed
Solid tumors
Global
IMM2510
VEGFxPD-L1 (Bispecific molecule)
Solid tumors
China (NMPA)
Global
IMM2510
View Details
IMM27M
CTLA-4 ADCC+
(mAb)
Solid tumors
China (NMPA)
Global
IMM27M
View Details
IMM40H
CD70
(mAb)
Liquid/Solid tumors
China (NMPA) / US (FDA)
Global
IMM40H
View Details
IMM01 + Azacitidine
+
-
合作企业:
靶点(结构):
CD47 (SIRPα-Fc fusion protein)
适应症:
AML, MDS, CMML
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA)
IMM01 + Tislelizumab
+
-
合作企业:
靶点(结构):
CD47+PD-1
适应症:
cHL, Solid tumor
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA)
IMM01 + Inetetamab
+
-
合作企业:
靶点(结构):
CD47+HER2
适应症:
HER2-positive solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA)
IMM01 + Bortezomib+ Dexamethasonum
+
-
合作企业:
靶点(结构):
CD47
适应症:
MM
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA)
IMM0306 Monotherapy
+
-
合作企业:
靶点(结构):
CD47xCD20 (Bispecific molecule)
适应症:
Indolent B-NHL
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA) / US (FDA)
IMM0306 + Lenalidomide
+
-
合作企业:
靶点(结构):
CD47xCD20 (Bispecific molecule)
适应症:
B-NHL
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA)
IMM2902
+
-
合作企业:
靶点(结构):
CD47xHER2 (Bispecific molecule)
适应症:
HER2-positive and low-expressing solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA) / US (FDA)
IMM2520
+
-
合作企业:
靶点(结构):
CD47xPD-L1 (Bispecific molecule)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA) / US (FDA)
IMM47
+
-
合作企业:
靶点(结构):
CD24 (mAb)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA) / US (FDA)
IMM4701
+
-
合作企业:
靶点(结构):
CD47xCD24 (Bispecific molecule)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
IMM2547
+
-
合作企业:
靶点(结构):
CD24xPD-L1 (Bispecific molecule)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
IMM51
+
-
合作企业:
靶点(结构):
IL-8 (mAb)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
IMM38
+
-
合作企业:
靶点(结构):
NKG2A (mAb)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
IMM50
+
-
合作企业:
靶点(结构):
PSGL-1 (mAb)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
IMM62
+
-
合作企业:
靶点(结构):
Undisclosed
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
IMM2510
+
-
合作企业:
靶点(结构):
VEGFxPD-L1 (Bispecific molecule)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA)
IMM27M
+
-
合作企业:
靶点(结构):
CTLA-4 ADCC+ (mAb)
适应症:
Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA)
IMM40H
+
-
合作企业:
靶点(结构):
CD70 (mAb)
适应症:
Liquid/Solid tumors
商业权利:
Global
发现
临床前
IND/IND
准备
Ia/Ⅰ期
Ib/Ⅱ期
Ⅲ期/关键性
试验
China (NMPA) / US (FDA)
Policy on Investigational Drugs

At Immuneonco, we follow the purpose of "Developing first-class new drugs, Benefitting tumor patients". We also are committed to providing access to therapies that are not yet approved for use to people who are suffering from a serious or life-threatening illness or condition and might potentially benefit from our medicines.

To do that, Immuneonco has developed the Access to Investigational Drugs Policy. It outlines important considerations we take into account when evaluating a doctor's request to use investigational drugs in a patient with a serious or life-threatening illness or condition.

Latest Development
0.097123s